Key result
Bivalirudin enables successful on-pump bypass in HIT using plasma-modified ACT monitoring.
Why the study?
Heparin-induced thrombocytopenia complicates anticoagulation management during cardiac surgery and requires alternative agents with nonconventional monitoring assays.
Does bivalirudin monitored by plasma-modified ACT provide safe anticoagulation in a patient with HIT undergoing on-pump cardiopulmonary bypass surgery?
Case Report (n=1)
No
Does bivalirudin monitored by plasma-modified ACT provide safe anticoagulation in a patient with HIT undergoing on-pump cardiopulmonary bypass surgery?
Plasma-modified ACT can be successfully used to monitor bivalirudin anticoagulation during on-pump cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
Answers are grounded in this paper and cite their sources.
May support bivalirudin anticoagulation during CPB in HIT; leaves open prospective validation of plasma-modified ACT monitoring.
Heparin-induced thrombocytopenia (HIT) is a problem of growing significance and concern, affecting an estimated 1–3% of patients among those receiving an estimated 10 million heparin exposures annually in the United States. The prevalence of heparin antibodies has been reported as at least 12.7% in the general cardiac surgery population before surgery and 42% following surgery (1). Various management techniques for anticoagulation in these patients have been proposed. Many of these alternative agents present additional risks for bleeding and efficacy and, furthermore, require the use of nonconventional monitoring assays to assess the level of anticoagulation achieved adequately. We report here the successful use of bivalirudin anticoagulation on pump, with no additional morbidity, and the first reported use of the plasma-modified ACT (activated clotting time) test, a simple modification of the standard ACT assay, to monitor the anticoagulant effect of bivalirudin.
No takes yet. Share an insight, caveat, or question.
Jabr et al. (2004) conducted a case report in Heparin-Induced Thrombocytopenia (HIT) (n=1). Bivalirudin monitored with plasma-modified ACT was evaluated on Successful anticoagulation and monitoring. Bivalirudin provided effective anticoagulation for on-pump cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia, and the plasma-modified ACT test successfully monitored its effect.
Synapse has enriched 10 related papers. Consider them for comparative context: